A biodegradable long-term contraceptive implant with steady levonorgestrel release based on PLGA microspheres embedded in PCL-coated implant

A dataset on formulation parameters and characteristics of drug-loaded PLGA microparticles

Polymer microparticles (MPs) are widely used to create long-acting injectable formulations due to their ability to enable sustained drug release. This feature can significantly benefit chronic disease management by reducing dosing frequency and improving patient adherence. To support the design and development of polymer MPs, we have compiled a dataset on MPs formed from poly(lactide-co-glycolide) (PLGA), the most commonly used polymer in commercial MP drug products. This dataset, derived from the literature, covers 321 in vitro release studies involving 89 different drugs. It aims to streamline future MP development by providing a reference for the current PLGA MP design space and supporting data-driven approaches such as machine learning. Published with open access, this dataset encourages broad utilization and aims to expand the range of available MP formulations.

Progestins of today and tomorrow

PURPOSE OF REVIEW

To review the current literature on the multiple types and uses of progestins in reproductive healthcare.

RECENT FINDINGS

Progestins for contraceptive use are available in multiple forms, with the ongoing development of transdermal, intravaginal, and male contraception formulations. Noncontraceptive use of progestins often overlaps with contraceptive indications, which allows for simultaneous multipurpose progestin use, especially in reproductive-aged patients. More studies are needed to determine contraceptive doses of progestins used for noncontraceptive purposes. Side effect profiles of progestins are dependent on their formulation and cross-reactivity with other steroid receptors. Development of newer progestins includes manipulating pharmacologic properties to avoid undesired side effects.

SUMMARY

Progestins have multiple uses in reproductive healthcare, including contraception, menstrual suppression, endometrial protection, and hormonal replacement therapy. The development of progestins for these indications can expand therapy for people with contraindications to estrogen-based hormonal therapy.